Yo-El Ju

Last updated

Yo-El Ju
Ju photo.jpg
Born
South Korea
Nationality South Korean
American
Alma mater Harvard college (B.A.), Columbia University Vagelos College of Physicians and Surgeons (M.D.)
Scientific career
Fields Sleep medicine, neurology
Institutions Washington University in St. Louis
Website https://sites.wustl.edu/yoelju/

Yo-El Ju is the Barbara Burton and Reuben Morriss III Professor of Neurology at the Washington University School of Medicine. She co-directs the Center on Biological Rhythms and Sleep (COBRAS) and is a member of the Hope Center for Neurological Diseases at Washington University. [1] [2] Clinically, she sees patients at Barnes-Jewish Hospital for parasomnia, narcolepsy, restless legs syndrome, and obstructive sleep apnea. [3] Ju's team has made multiple significant contributions to the field of sleep medicine and neurology in unveiling the complex relationship between sleep, amyloid deposition and neurodegenerative diseases such as Alzheimer's, opening new possibilities for clinical treatment. As of April 2023, the most cited work from her lab is their 2017 paper in Brain: A Journal of Neurology that showed cerebrospinal fluid (CSF) amyloid-beta protein level increases due to slow-wave sleep disruption. [4]

Contents

Early life and education

Ju was born in 1979 in South Korea. She attended Rift Valley Academy in Kijabe, Kenya for high school and later transferred to Fairfax High School in Los Angeles, U.S. She attended Harvard College for her undergraduate studies, graduating Magna Cum Laude in 2001 with a B.A. in biology. While studying at Harvard, she received the John Harvard College Scholarship (awarded to top 5% of class) and conducted research in neuronal cell biology and tissue engineering in the lab of Paul Janmey and Thomas Stossel under the mentorship of Lisa A. Flanagan. [5] [6] Ju went on to obtain her M.D. in 2005 from Columbia University Vagelos College of Physicians and Surgeons, where she was a member of Alpha Omega Alpha, a national medical honor society, and won the Glasgow-Rubin Achievement Award for women graduating in the top 10% of their class. After graduating from medical school, Ju moved to Washington University in St. Louis, completing a residency in neurology in 2009. [3] After this, Ju went on to specialize in sleep medicine, completing clinical and research fellowships in the discipline of the Washington University Multidisciplinary Sleep Medicine Center from 2009 to 2011, where she examined the relationship between Alzheimer's disease and circadian rhythms. [3] [7] During this period, Ju also studied rapid eye movement (REM) sleep behavior disorder with an eye to future treatments. [8] [9] Ju obtained her M.S. in Clinical Investigation from Washington University in St. Louis in 2015.

Scientific career

Ju started working as an Assistant Professor in the Department of Neurology at Washington University School of Medicine in 2011 and is currently the Barbara Burton and Reuben Morriss III Professor of Neurology. The Yo-El Ju Lab studies sleep and neurodegenerative diseases, focusing on two areas: sleep and Alzheimer's disease, and REM sleep behavior disorder and its relationship to synucleinopathies such as Parkinson's disease. The lab's projects include studying the effect of slow-wave sleep on amyloid-beta dynamics; REM sleep behavior disorder; sleep and circadian rhythms in Alzheimer's disease; as well as biomarkers of Alzheimer's disease in sleep and electroencephalography (EEG).

In May 2013, a team including Ju and her mentor David Holtzman showed that sleep quality, but not necessarily sleep quantity, is associated with amyloid deposition in preclinical Alzheimer's disease, publishing their findings in JAMA Neurology . [10] This study was critical in identifying a greater temporal window for key clinical interventions to be made to address sleep abnormalities because it was the first to show that changes in sleep are associated with Alzheimer's disease brain changes prior to symptom onset (in preclinical disease). It also identified an unexpected trend toward increased time in bed and amyloid deposition. These findings relate to a number of subsequent influential findings, including that sleep consolidation, or reducing the time in bed to match the time asleep, can attenuate the effects of the apolipoprotein E ε4 genotype on the development of incident Alzheimer's Disease. [11] Many Alzheimer’s interventions involve regulating other aspects of patients’ sleep as well. [12] [13] [14]

In addition to her 2013 finding on sleep quality being associated with amyloid deposition, Ju also highlighted how it may be the case that sleep and Alzheimer's biomarkers influence each other in a bidirectional relationship: the sleep-wake cycle influences amyloid deposition in the brain, but amyloid-beta deposition may also lead to altered sleep-wake patterns. In 2014, Ju published a review paper in Nature Reviews Neurology that underscored how neurodegenerative diseases and sleep may influence each other in a bidirectional relationship, and how that may have important implications for how Alzheimer's disease is diagnosed and treated. [15] This has important implications for how individuals with obstructive sleep apnea and other sleep problems should be treated to reduce their risk of developing dementia and how measures of sleep quality may be treated as preclinical markers of Alzheimer's disease.

In 2016, Ju's team published a paper in Annals of Neurology showing that CSF levels of amyloid-beta are decreased in obstructive sleep apnea patients, despite the finding that these patients had lower slow wave activity, a sign of a lull in cortical neuron synaptic activity. [16] This finding was unexpected because slow wave activity is negatively correlated with CSF amyloid beta levels in individuals without obstructive sleep apnea (the opposite of what was observed in individuals with obstructive sleep apnea), and because its findings questioned previous findings of increased intracellular amyloid-beta in obstructive sleep apnea. Importantly, this study identified key shortcomings in previously proposed model mechanisms used to explain the field's previous understanding of an association between obstructive sleep apnea and Alzheimer's Disease. Ju and colleagues proposed an alternative mechanism that draws upon CSF pulsatility and respiration-driven CSF bulk flow, specifically hypothesizing that obstructive episodes during obstructive sleep apnea result in elevated intrathoracic and intracranial pressure, the latter of which may impede the flow of metabolites like amyloid beta from the brain interstitial space into the CSF. This has broadened the interests of researchers to reconsider the magnitude of the role hypoxia and sleep fragmentation play in neurodegeneration and cognitive decline in individuals with obstructive sleep apnea, and to also consider downstream effects of apneic episodes on metabolite build-up, inflammation, and cerebrovascular changes as part of the causal pathway.

Later on, in 2017, Ju led a study published in Brain: A Journal of Neurology that found CSF amyloid-beta protein level increases as a result of slow-wave sleep deprivation. [17] [18] This finding was particularly significant because while researchers had previously known that sleep deprivation increases amyloid-beta levels, and that sleep disorders are associated with Alzheimer's disease pathology, sleep is a heterogenous state and the specific aspects of sleep associated with neurodegeneration had not been examined. This finding opened the field for future studies that specifically target preservation or enhancement of slow-wave sleep to prevent amyloid-beta deposition in Alzheimer's disease pathology. Subsequent studies have supported this finding and provided additional evidence for slow wave activity to be inversely related to tau pathology in addition to amyloid-beta. [19]

Ju was the senior author on a 2018 paper in JAMA Neurology studying how circadian rhythms are disturbed in preclinical Alzheimer's disease. [20] After measuring circadian rhythms using wrist actigraphy data and Alzheimer's disease pathology using Pittsburgh-Compound B (PiB) amyloid imaging and CSF phosphorylated-tau as biomarkers, Ju and colleagues found that there is rest-activity circadian rhythm fragmentation in individuals with preclinical Alzheimer's disease, and that circadian dysfunction occurs in older individuals independent of preclinical Alzheimer's disease pathology. These findings further highlight the association between Alzheimer's disease and the body's biological clock, in addition to underlining a need for 24-hour care for Alzheimer's patients, and have been supported by subsequent research. [21] In addition, they have opened many lines of investigation into how changes in circadian rhythms differ between normal aging and neurodegeneration, the molecular mechanisms of circadian rhythm changes, and the directionality of the role of amyloid beta in circadian rhythm fragmentation.

Ju collaborates with Washington University colleagues in studying sleep/circadian function and Alzheimer's disease, including David Holtzman, Erik Musiek, and Brendan Lucey, among others. Currently, Ju's research interests include using electroencephalography to predict Alzheimer's disease and evaluating the relationship between circadian rhythm dysfunction and tau protein deposition in the brain. She is also studying REM sleep behavior disorder, a sleep disorder that in many cases precedes a diagnosis of Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy—together called synucleinopathies.

Personal life

Ju currently lives in St. Louis, Missouri. She married in 2006 and divorced in 2022. [22] She is the mother of two children, born in 2014 and 2017.

Memberships and certifications

Ju holds memberships in the American Academy of Sleep Medicine, the American Academy of Neurology, the American Neurological Association, for which she has served as the co-chair of the Sleep and Clocks Special Interest Group from 2019 to 2021, and the International REM Sleep Behavior Disorder Study Group, for which she has served as executive board from 2015 to 2019 and secretary from 2017 to 2019. Ju is board certified in neurology and sleep medicine by the American Board of Psychiatry and Neurology. [3]

Awards and grants

Ju has won multiple NIH grants, including a roughly 35 million dollar grant to the North American Prodromal Synucleinopathy (NAPS) Consortium where she is the principal investigator together with Bradley Boeve and Ronald Postuma. [2] [23] Ju was ranked the 14th highest NIH-funded investigator in neurology in 2022. [24] Additionally, Ju has won multiple prestigious awards for her research, including the American Academy of Sleep Medicine Parasomnia Section Investigator Award in 2010, the World Association of Sleep Medicine Young Investigator Award in 2013, and the American Academy of Neurology Wayne Hening Sleep Medicine Investigator Award in 2018. [1]

Selected publications

Related Research Articles

<span class="mw-page-title-main">Sleep apnea</span> Disorder involving pauses in breathing during sleep

Sleep apnea, also spelled sleep apnoea, is a sleep disorder in which pauses in breathing or periods of shallow breathing during sleep occur more often than normal. Each pause can last for a few seconds to a few minutes and they happen many times a night. In the most common form, this follows loud snoring. A choking or snorting sound may occur as breathing resumes. Because the disorder disrupts normal sleep, those affected may experience sleepiness or feel tired during the day. In children, it may cause hyperactivity or problems in school.

<span class="mw-page-title-main">Sleep disorder</span> Medical disorder of a persons sleep patterns

A sleep disorder, or somnipathy, is a medical disorder of an individual's sleep patterns. Some sleep disorders are severe enough to interfere with normal physical, mental, social and emotional functioning. Sleep disorders are frequent and can have serious consequences on patients’ health and quality of life. Polysomnography and actigraphy are tests commonly ordered for diagnosing sleep disorders.

Hypersomnia is a neurological disorder of excessive time spent sleeping or excessive sleepiness. It can have many possible causes and can cause distress and problems with functioning. In the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), hypersomnolence, of which there are several subtypes, appears under sleep-wake disorders.

<span class="mw-page-title-main">Amyloid beta</span> Group of peptides

Amyloid beta denotes peptides of 36–43 amino acids that are the main component of the amyloid plaques found in the brains of people with Alzheimer's disease. The peptides derive from the amyloid-beta precursor protein (APP), which is cleaved by beta secretase and gamma secretase to yield Aβ in a cholesterol-dependent process and substrate presentation. Aβ molecules can aggregate to form flexible soluble oligomers which may exist in several forms. It is now believed that certain misfolded oligomers can induce other Aβ molecules to also take the misfolded oligomeric form, leading to a chain reaction akin to a prion infection. The oligomers are toxic to nerve cells. The other protein implicated in Alzheimer's disease, tau protein, also forms such prion-like misfolded oligomers, and there is some evidence that misfolded Aβ can induce tau to misfold.

<span class="mw-page-title-main">Amyloid plaques</span> Extracellular deposits of the amyloid beta protein

Amyloid plaques are extracellular deposits of the amyloid beta (Aβ) protein mainly in the grey matter of the brain. Degenerative neuronal elements and an abundance of microglia and astrocytes can be associated with amyloid plaques. Some plaques occur in the brain as a result of aging, but large numbers of plaques and neurofibrillary tangles are characteristic features of Alzheimer's disease. The plaques are highly variable in shape and size; in tissue sections immunostained for Aβ, they comprise a log-normal size distribution curve, with an average plaque area of 400-450 square micrometers (µm²). The smallest plaques, which often consist of diffuse deposits of Aβ, are particularly numerous. Plaques form when Aβ misfolds and aggregates into oligomers and longer polymers, the latter of which are characteristic of amyloid.

<span class="mw-page-title-main">Cerebral amyloid angiopathy</span> Disease of blood vessels of the brain

Cerebral amyloid angiopathy (CAA) is a form of angiopathy in which amyloid beta peptide deposits in the walls of small to medium blood vessels of the central nervous system and meninges. The term congophilic is sometimes used because the presence of the abnormal aggregations of amyloid can be demonstrated by microscopic examination of brain tissue after staining with Congo red. The amyloid material is only found in the brain and as such the disease is not related to other forms of amyloidosis.

The International Classification of Sleep Disorders (ICSD) is "a primary diagnostic, epidemiological and coding resource for clinicians and researchers in the field of sleep and sleep medicine". The ICSD was produced by the American Academy of Sleep Medicine (AASM) in association with the European Sleep Research Society, the Japanese Society of Sleep Research, and the Latin American Sleep Society. The classification was developed as a revision and update of the Diagnostic Classification of Sleep and Arousal Disorders (DCSAD) that was produced by both the Association of Sleep Disorders Centers (ASDC) and the Association for the Psychophysiological Study of Sleep and was published in the journal Sleep in 1979. A second edition, called ICSD-2, was published by the AASM in 2005. The third edition, ICSD-3, was released by the AASM in 2014. A text revision of the third edition (ICSD-3-TR) was published in 2023 by the AASM.

<span class="mw-page-title-main">Alzheimer's disease</span> Progressive neurodegenerative disease

Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, and is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.

Sundowning, or sundown syndrome, is a neurological phenomenon associated with increased confusion and restlessness in people with delirium or some form of dementia. It is most commonly associated with Alzheimer's disease but also found in those with other forms of dementia. The term "sundowning" was coined by nurse Lois K. Evans in 1987 due to the timing of the person's increased confusion beginning in the late afternoon and early evening. For people with sundown syndrome, a multitude of behavioral problems begin to occur and are associated with long term adverse outcomes. Sundowning seems to occur more frequently during the middle stages of Alzheimer's disease and mixed dementia and seems to subside with the progression of the person's dementia. People are generally able to understand that this behavioral pattern is abnormal. Research shows that 20–45% of people with Alzheimer's will experience some variation of sundowning confusion. However, despite lack of an official diagnosis of sundown syndrome in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), there is currently a wide range of reported prevalence.

Solanezumab is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector for patients with Alzheimer's disease. The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials.

Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study that aims to improve clinical trials for the prevention and treatment of Alzheimer's disease (AD). This cooperative study combines expertise and funding from the private and public sector to study subjects with AD, as well as those who may develop AD and controls with no signs of cognitive impairment. Researchers at 63 sites in the US and Canada track the progression of AD in the human brain with neuroimaging, biochemical, and genetic biological markers. This knowledge helps to find better clinical trials for the prevention and treatment of AD. ADNI has made a global impact, firstly by developing a set of standardized protocols to allow the comparison of results from multiple centers, and secondly by its data-sharing policy which makes available all at the data without embargo to qualified researchers worldwide. To date, over 1000 scientific publications have used ADNI data. A number of other initiatives related to AD and other diseases have been designed and implemented using ADNI as a model. ADNI has been running since 2004 and is currently funded until 2021.

Irregular sleep–wake rhythm disorder (ISWRD) is a rare form of circadian rhythm sleep disorder. It is characterized by numerous naps throughout the 24-hour period, no main nighttime sleep episode, and irregularity from day to day. Affected individuals have no pattern of when they are awake or asleep, may have poor quality sleep, and often may be very sleepy while they are awake. The total time asleep per 24 hours is normal for the person's age. The disorder is serious—an invisible disability. It can create social, familial, and work problems, making it hard for a person to maintain relationships and responsibilities, and may make a person home-bound and isolated.

<span class="mw-page-title-main">Cholinergic neuron</span> Type of nerve cell

A cholinergic neuron is a nerve cell which mainly uses the neurotransmitter acetylcholine (ACh) to send its messages. Many neurological systems are cholinergic. Cholinergic neurons provide the primary source of acetylcholine to the cerebral cortex, and promote cortical activation during both wakefulness and rapid eye movement sleep. The cholinergic system of neurons has been a main focus of research in aging and neural degradation, specifically as it relates to Alzheimer's disease. The dysfunction and loss of basal forebrain cholinergic neurons and their cortical projections are among the earliest pathological events in Alzheimer's disease.

Classification of sleep disorders comprises systems for classifying medical disorders associated with sleep. Systems have changed, increasingly using technological discoveries to advance the understanding of sleep and recognition of sleep disorders.

<span class="mw-page-title-main">Solriamfetol</span> Medication used for the treatment of excessive sleepiness

Solriamfetol, sold under the brand name Sunosi, is a wakefulness-promoting medication used in the treatment of excessive sleepiness related to narcolepsy and sleep apnea. It is taken by mouth.

Sleep disorder is a common repercussion of traumatic brain injury (TBI). It occurs in 30%-70% of patients with TBI. TBI can be distinguished into two categories, primary and secondary damage. Primary damage includes injuries of white matter, focal contusion, cerebral edema and hematomas, mostly occurring at the moment of the trauma. Secondary damage involves the damage of neurotransmitter release, inflammatory responses, mitochondrial dysfunctions and gene activation, occurring minutes to days following the trauma. Patients with sleeping disorders following TBI specifically develop insomnia, sleep apnea, narcolepsy, periodic limb movement disorder and hypersomnia. Furthermore, circadian sleep-wake disorders can occur after TBI.

Anti-IgLON5 disease is a neurodegenerative autoimmune disease. It is marked by parasomnias and chorea - an involuntary movement disorder.

<span class="mw-page-title-main">David M. Holtzman</span> Medical researcher

David M. Holtzman is an American physician-scientist known for his work exploring the biological mechanisms underlying neurodegeneration, with a focus on Alzheimer's disease. Holtzman is former Chair of the Department of Neurology, Scientific Director of the Hope Center for Neurological Disorders, and associate director of the Knight Alzheimer's Disease Research Center at Washington University School of Medicine in St. Louis, Missouri. Holtzman's lab is known for examining how apoE4 contributes to Alzheimer's disease as well as how sleep modulates amyloid beta in the brain. His work has also examined the contributions of microglia to AD pathology.

Johanna H. Meijer is a Dutch scientist who has contributed significantly to the field of chronobiology. Meijer has made notable contributions to the understanding of the neural and molecular mechanisms of circadian pacemakers. She is known for her extensive studies of photic and non-photic effects on the mammalian circadian clocks. Notably, Meijer is the 2016 recipient of the Aschoff and Honma Prize, one of the most prestigious international prizes in the circadian research field. In addition to still unraveling neuronal mechanisms of circadian clocks and their applications to health, Meijer's lab now studies the effects of modern lifestyles on our circadian rhythm and bodily functions.

Alzheimer's disease (AD) in African Americans is becoming a rising topic of interest in AD care, support, and scientific research, as African Americans are disproportionately affected by AD. Recent research on AD has shown that there are clear disparities in the disease among racial groups, with higher prevalence and incidence in African Americans than the overall average. Pathologies for Alzheimer’s also seem to manifest differently in African Americans, including with neuroinflammation markers, cognitive decline, and biomarkers. Although there are genetic risk factors for Alzheimer’s, these account for few cases in all racial groups.

References

  1. 1 2 "Team". Yo-El Ju Lab. September 22, 2019. Retrieved April 10, 2023.
  2. 1 2 "Yo-El S. Ju, MD, MSCI". Sleep Medicine Center. March 18, 2021. Retrieved April 27, 2023.
  3. 1 2 3 4 "Yo-El S Ju, MD". Washington University Physicians. Retrieved April 23, 2023.
  4. ↑ "Yo-El Ju". scholar.google.com. Retrieved April 27, 2023.
  5. ↑ Flanagan, Lisa A.; Ju, Yo-El; Marg, Beatrice; Osterfield, Miriam; Janmey, Paul A. (December 20, 2002). "Neurite branching on deformable substrates". NeuroReport. 13 (18): 2411–2415. doi:10.1097/00001756-200212200-00007. ISSN   0959-4965. PMC   2408859 . PMID   12499839.
  6. ↑ Ju, Yo-El; Janmey, Paul A.; McCormick, Margaret E.; Sawyer, Evelyn S.; Flanagan, Lisa A. (April 1, 2007). "Enhanced neurite growth from mammalian neurons in three-dimensional salmon fibrin gels". Biomaterials. 28 (12): 2097–2108. doi:10.1016/j.biomaterials.2007.01.008. ISSN   0142-9612. PMC   1991290 . PMID   17258313.
  7. ↑ Huang, Yafei; Potter, Rachel; Sigurdson, Wendy; Santacruz, Anna; Shih, Shirley; Ju, Yo-El; Kasten, Tom; Morris, John C.; Mintun, Mark; Duntley, Stephen; Bateman, Randall J. (September 12, 2011). "Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system". Archives of Neurology. 69 (1): 51–58. doi:10.1001/archneurol.2011.235. ISSN   1538-3687. PMC   3254706 . PMID   21911660.
  8. ↑ Ju, Yo-El; Larson-Prior, Linda; Duntley, Stephen (February 12, 2011). "Changing demographics in REM sleep behavior disorder: possible effect of autoimmunity and antidepressants". Sleep Medicine. 12 (3): 278–283. doi:10.1016/j.sleep.2010.07.022. ISSN   1878-5506. PMID   21317035.
  9. ↑ Postuma, Ronald B.; Arnulf, Isabelle; Hogl, Birgit; Iranzo, Alex; Miyamoto, Tomoyuki; Dauvilliers, Yves; Oertel, Wolfgang; Ju, Yo-El; Puligheddu, Monica; Jennum, Poul; Pelletier, Amelie; Wolfson, Christina; Leu-Semenescu, Smaranda; Frauscher, Birgit; Miyamoto, Masayuki (May 30, 2012). "A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study". Movement Disorders. 27 (7): 913–916. doi:10.1002/mds.25037. ISSN   1531-8257. PMC   4043389 . PMID   22729987.
  10. ↑ Ju, Yo-El S.; McLeland, Jennifer S.; Toedebusch, Cristina D.; Xiong, Chengjie; Fagan, Anne M.; Duntley, Stephen P.; Morris, John C.; Holtzman, David M. (May 1, 2013). "Sleep quality and preclinical Alzheimer disease". JAMA Neurology. 70 (5): 587–593. doi:10.1001/jamaneurol.2013.2334. ISSN   2168-6157. PMC   3676720 . PMID   23479184.
  11. ↑ Lim, Andrew S. P.; Yu, Lei; Kowgier, Matthew; Schneider, Julie A.; Buchman, Aron S.; Bennett, David A. (December 1, 2013). "Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep". JAMA Neurology. 70 (12): 1544–1551. doi:10.1001/jamaneurol.2013.4215. ISSN   2168-6157. PMC   3859706 . PMID   24145819.
  12. ↑ Cordone, Susanna; Scarpelli, Serena; Alfonsi, Valentina; De Gennaro, Luigi; Gorgoni, Maurizio (April 19, 2021). "Sleep-Based Interventions in Alzheimer's Disease: Promising Approaches from Prevention to Treatment along the Disease Trajectory". Pharmaceuticals. 14 (4): 383. doi: 10.3390/ph14040383 . ISSN   1424-8247. PMC   8073746 . PMID   33921870.
  13. ↑ Bhandari, Tamara (February 25, 2022). "Does improving sleep reduce signs of early Alzheimer's disease?". Washington University School of Medicine in St. Louis. Retrieved April 23, 2023.
  14. ↑ MD, Andrew E. Budson (May 3, 2021). "Sleep well — and reduce your risk of dementia and death". Harvard Health. Retrieved April 23, 2023.
  15. ↑ Ju, Yo-El S.; Lucey, Brendan P.; Holtzman, David M. (December 24, 2013). "Sleep and Alzheimer disease pathology—a bidirectional relationship". Nature Reviews. Neurology. 10 (2): 115–119. doi:10.1038/nrneurol.2013.269. ISSN   1759-4766. PMC   3979317 . PMID   24366271.
  16. ↑ Ju, Yo-El S.; Finn, Mary Beth; Sutphen, Courtney L.; Herries, Elizabeth M.; Jerome, Gina M.; Ladenson, Jack H.; Crimmins, Daniel L.; Fagan, Anne M.; Holtzman, David M. (June 1, 2016). "Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid". Annals of Neurology. 80 (1): 154–159. doi:10.1002/ana.24672. ISSN   1531-8249. PMC   5120585 . PMID   27129429.
  17. ↑ Ju, Yo-El S.; Ooms, Sharon J.; Sutphen, Courtney; Macauley, Shannon L.; Zangrilli, Margaret A.; Jerome, Gina; Fagan, Anne M.; Mignot, Emmanuel; Zempel, John M.; Claassen, Jurgen A. H. R.; Holtzman, David M. (August 1, 2017). "Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels". Brain: A Journal of Neurology. 140 (8): 2104–2111. doi:10.1093/brain/awx148. ISSN   1460-2156. PMC   5790144 . PMID   28899014.
  18. ↑ Mander, Bryce A.; Winer, Joseph R.; Walker, Matthew P. (August 1, 2017). "A restless night makes for a rising tide of amyloid". Brain: A Journal of Neurology. 140 (8): 2066–2069. doi: 10.1093/brain/awx174 . ISSN   1460-2156. PMID   28899024.
  19. ↑ Lucey, Brendan P.; McCullough, Austin; Landsness, Eric C.; Toedebusch, Cristina D.; McLeland, Jennifer S.; Zaza, Aiad M.; Fagan, Anne M.; McCue, Lena; Xiong, Chengjie; Morris, John C.; Benzinger, Tammie L. S.; Holtzman, David M. (January 9, 2019). "Reduced non–rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease". Science Translational Medicine. 11 (474): eaau6550. doi:10.1126/scitranslmed.aau6550. ISSN   1946-6234. PMC   6342564 . PMID   30626715.
  20. ↑ Musiek, Erik S.; Bhimasani, Meghana; Zangrilli, Margaret A.; Morris, John C.; Holtzman, David M.; Ju, Yo-El S. (May 1, 2018). "Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease". JAMA Neurology. 75 (5): 582–590. doi:10.1001/jamaneurol.2017.4719. ISSN   2168-6157. PMC   5885197 . PMID   29379963.
  21. ↑ Duncan, M. J.; Guerriero, L. E.; Kohler, K.; Beechem, L. E.; Gillis, B. D.; Salisbury, F.; Wessel, C.; Wang, J.; Sunderam, S.; Bachstetter, A. D.; O'Hara, B. F.; Murphy, M. P. (January 15, 2022). "Chronic Fragmentation of the Daily Sleep-Wake Rhythm Increases Amyloid-beta Levels and Neuroinflammation in the 3xTg-AD Mouse Model of Alzheimer's Disease". Neuroscience. 481: 111–122. doi:10.1016/j.neuroscience.2021.11.042. ISSN   0306-4522. PMC   8941625 . PMID   34856352.
  22. ↑ "Weddings". The New York Times. June 25, 2006. ISSN   0362-4331 . Retrieved April 10, 2023.
  23. ↑ Bhandari, Tamara (October 5, 2021). "$35 million to support study of sleep disorder linked to neurodegeneration". Washington University School of Medicine in St. Louis. Retrieved April 10, 2023.
  24. ↑ "BRIMR Rankings of NIH Funding in 2022". brimr.org. February 9, 2023. Retrieved April 23, 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.